Entrada Therapeutics, Inc.

TRDA

$7.17

-1.78%

N/A-$0.13

Healthcare

Biotechnology

NASDAQ

Active Trading

Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range ...

Key Metrics of TRDA

Snapshot

Latest / TTM · 6 periods

Market Cap

$278.34M

ROCE

-63.6%

EV / EBITDA

-1.38x

-19.4% YoY

FCF Yield

-48.3%

-17.8% YoY

Cash Conversion Cycle

29.4d

Current Ratio

10.89

Quick take

TTM —

Positive CCC

Key Metrics

Latest / TTM · 6 periods

Valuation trend

Valuation trend table

Metric	2021	2022	2023	2024	2025	TTM
Market CapTotal market value of all shares outstanding.	$534.56M	$423.09M	$498.73M	$645.02M	$425.30M	$278.34M
Enterprise ValueCompany value including debt and cash adjustments.	$243.50M	$403.86M	$499.36M	$603.02M	$385.84M	$227.61M
EV / SalesHow many dollars investors pay per dollar of sales.	0.00x	0.00x	3.87x	2.86x	15.18x	48.57x
EV / EBITDAValuation multiple versus operating earnings before non-cash charges.	-4.87x	-4.48x	33.52x	8.58x	-2.71x	-1.38x
Net Debt / EBITDALeverage ratio using net debt divided by EBITDA.	5.82	0.21	0.04	-0.60	0.28	0.31

Returns + ROCE gauge

ROCE latest

-63.6%

Prev year -44.2%

Returns + ROCE gauge table

Metric	2021	2022	2023	2024	2025	TTM
ROEProfit generated from shareholders' equity.	-17.1%	-44.5%	-2.8%	15.3%	-47.0%	-57.6%
ROAProfit generated from total assets.	-16.7%	-37.5%	-1.4%	12.5%	-38.1%	-55.5%
ROICReturn generated on invested operating capital.	-17.2%	-41.6%	-2.2%	13.6%	-41.1%	-60.5%
ROCEOperating return on long-term capital used.	-17.1%	-42.3%	-1.0%	9.7%	-44.2%	-63.6%
Earnings YieldEarnings as a percentage of market value.	-9.6%	-22.4%	-1.3%	10.2%	-33.8%	-54.8%

Cash flow quality

Cash flow quality table

Metric	2021	2022	2023	2024	2025	TTM
FCFFCash flow available to all capital providers.	$-55.44M	$-94.04M	$134.19M	$-44.72M	$-129.55M	$-134.35M
FCFECash flow available to equity holders after debt flows.	$-55.44M	$-96.67M	$134.19M	$-44.72M	$-129.55M	$-134.35M
FCF YieldFree cash flow divided by market capitalization.	-10.4%	-22.8%	26.9%	-6.9%	-30.5%	-48.3%
Income QualityHow well accounting earnings are backed by cash flow.	0.99	0.99	-20.91	-0.63	0.89	0.81
Capex / OCFShare of operating cash flow spent on capital expenditures.	-9.0%	-3.1%	4.0%	-7.6%	-0.8%	-0.2%

Operating efficiency

Operating efficiency table

Metric	2021	2022	2023	2024	2025	TTM
DSOAverage days to collect cash from customers.	0.0d	0.0d	16.6d	6.4d	37.0d	63.6d
DIOAverage days inventory stays before being sold.	0.0d	0.0d	0.0d	0.0d	0.0d	0.0d
DPOAverage days the company takes to pay suppliers.	0.0d	0.0d	0.0d	0.0d	204.0d	34.1d
Operating CycleTime from buying inventory to collecting receivables.	0.0d	0.0d	16.6d	6.4d	37.0d	63.6d
Cash Conversion CycleNet days cash is tied in operations.	0.0d	0.0d	16.6d	6.4d	-167.0d	29.4d

Snapshot

Latest / TTM: —

Market Cap

$278.34M

ROE

-57.6%

FCF Yield

-48.3%

Current Ratio

10.89

Upstream

Vertex Pharmaceuticals IncorporatedNASDAQ:VRTX Thermo Fisher Scientific Inc. (Patheon Pharma Services)NYSE:TMO Catalent, Inc.NYSE:CTLT WuXi AppTec Co., Ltd.HKEx:2359 Charles River Laboratories International, Inc.NYSE:CRL Fortrea Holdings Inc.NASDAQ:FTREVelocity Clinical Research, Inc.Azenta Life Sciences (formerly Brooks Life Sciences)NASDAQ:AZTACordenPharma InternationalBachem Holding AGSWX:BANBTwist Bioscience CorporationNASDAQ:TWST Agilent Technologies, Inc.NYSE:A

Downstream

Vertex Pharmaceuticals IncorporatedNASDAQ:VRTXPatients with Duchenne Muscular Dystrophy (DMD)Patients with Usher Syndrome Type 2A (USH2A) / Inherited Retinal DiseasesPatients with Myotonic Dystrophy Type 1 (DM1)

Proxies

Dyne Therapeutics, Inc.NASDAQ:DYN PepGen Inc.NASDAQ:PEPG Sarepta Therapeutics, Inc.NASDAQ:SRPT Wave Life Sciences Ltd.NASDAQ:WVE

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

No matching stocks found

Entrada Therapeutics, Inc.

Key Metrics of TRDA

Key Metrics

Valuation trend

Returns + ROCE gauge

Cash flow quality

Operating efficiency

Snapshot

Supply Chain of TRDA

Upstream

Downstream

Proxies

Key Metrics of TRDA

Key Metrics

Valuation trend

Returns + ROCE gauge

Cash flow quality

Operating efficiency

Snapshot

Supply Chain of TRDA

Upstream

Downstream

Proxies